Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study.

Oncologist · 2025 · PMC11799859 · PMID 39912344

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

In this subset, a benefit in PFS was observed as well as a nonsignificant trend toward benefit in overall survival, reinforcing tivozanib as a viable option in this setting.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.